RBM6 and cancer: The sensitivity to PARPi was also evident in RBM6-deficient HeLa cells (Supplementary Figure S17C), suggesting that the ‘BRCAness’ phenotype of RBM6-deficient cells displays synthetic lethal interaction with PARPi in a broader range of cancer cells.